 Ault Global Holdings Inc NYSE: DPW, a diversified holding company, has announced that Alzamend Neuro Inc NASDAQ: ALZN has submitted an investigational new drug application to the FDA for a Phase 1 study of AL001. The Phase 1 study is designed to determine clinically safe and appropriate AL001 dosing in future studies. 